Skip to main content

Gossamer Bio, Inc 10-Q for FY2026 Q3

Gossamer Bio, Inc. (GOSS)

10-Q 2026-11-10 For: 2026-09-30
View Original
Added on November 10, 2026

About this 10-Q

Gossamer Bio, Inc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Gossamer Bio, Inc. reacquired worldwide seralutinib rights from Chiesi in July 2026 and submitted an NDA for PAH in September 2026. It had $51.2 million in cash, cash equivalents and marketable securities as of September 30, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$38.43M
up 189.1% from $13.29M a year earlier
Net loss
$48.07M
compared with a net loss of $48.22M a year earlier
Diluted EPS
-$7.36
compared with -$16.92 a year earlier